Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Free Cash Flow (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Free Cash Flow for 8 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow changed N/A to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$24.7 million for FY2025, 25.39% up from the prior year.
  • Free Cash Flow for Q4 2025 was $2.6 million at Actinium Pharmaceuticals, up from -$7.6 million in the prior quarter.
  • The five-year high for Free Cash Flow was $27.6 million in Q2 2022, with the low at -$15.2 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$5.4 million, with a median of -$7.4 million recorded in 2024.
  • The sharpest move saw Free Cash Flow skyrocketed 695.22% in 2022, then plummeted 161.8% in 2023.
  • Over 5 years, Free Cash Flow stood at -$5.1 million in 2021, then crashed by 54.28% to -$7.8 million in 2022, then rose by 3.9% to -$7.5 million in 2023, then tumbled by 59.88% to -$12.0 million in 2024, then soared by 122.11% to $2.6 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $2.6 million, -$7.6 million, and -$12.0 million for Q4 2025, Q1 2025, and Q3 2024 respectively.